Posted by Michael Wonder on 22 Oct 2024
Nine provinces approve accelerated public reimbursement of diffuse large B-cell lymphoma treatment under new early access process
21 October 2024 - AbbVie today announced that nine provinces have provided accelerated public coverage of Epkinly.
Epkinly is a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma transformed from indolent lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B and is indicated after two or more lines of systemic therapy in patients who have previously received or are unable to receive CAR-T cell therapy.
